U.S. markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
70.54-0.92 (-1.29%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close71.46
Bid70.50 x 1200
Ask70.65 x 900
Day's Range70.00 - 71.62
52 Week Range69.56 - 181.83
Avg. Volume1,718,720
Market Cap5.602B
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-7.11
Earnings DateMay 04, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est132.32
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is SRPT Stock A Buy or Sell?
    Insider Monkey

    Is SRPT Stock A Buy or Sell?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 887 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • Is Sarepta Therapeutics Worthy of Redemption?
    Motley Fool

    Is Sarepta Therapeutics Worthy of Redemption?

    A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.

  • Motley Fool

    Sarepta Therapeutics' Long-Term Potential Is in Flux

    Sarepta Therapeutics (NASDAQ: SRPT) continues to make progress selling its drugs to treat Duchenne muscular dystrophy (DMD). In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss Sarepta's fourth-quarter results and why investors should still be focused on the company's pipeline. Brian Orelli: Moving on to Sarepta Therapeutics, which is focused on Duchenne's muscular dystrophy.